Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as nifedipine, that preferentially act on vascular smooth muscle and verapamil that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities. Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.
Oral
Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.
Indicated for use to improve exercise tolerance in patients with chronic stable angina.
Indicated for the management of variant angina (Prinzmetal's angina).
Intravenous
Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.
Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.
Off-label
Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.
Fortrea CRU, Madison ( Site 0001), Madison, Wisconsin, United States
Celerion (Site 0002), Lincoln, Nebraska, United States
Labcorb CRU, Madison (Site 0001), Madison, Wisconsin, United States
ICON (Site 0001), Lenexa, Kansas, United States
Celerion ( Site 0001), Tempe, Arizona, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Sultan Qaboos University Hospital, Muscat, Al-khod, Oman
Service des Maladies Infectieuses et Tropicales, Fort-de-France, France
respiratory department Amiens Hospital, Amiens, France
Service de Maladies infectieuses et tropicales, Amiens, France
Universitäres Herzzentrum Zürich, Universitätsspital Zürich, Zürich, Switzerland
Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany
Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany
Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Bangkoknoi, Thailand
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.